Drugs / Matrix
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07372989 | Feb 2026 → Jun 2027 expected | interstitial lung disease | Maule Stem Cell Research Institute, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Matrix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07372989 ↗ |
| Known as | HAF-Matrix | “This is a Phase I, pilot clinical trial designed to evaluate the safety and exploratory efficacy of nebulized diluted amniotic fluid, Matrix (HAF-Matrix) in adults with...” NCT07372989 ↗ |
| Modality | Other / unclassified | “1.0 mL of Matrix (Exosomes)” NCT07372989 ↗ |
| Route | Inhaled | “Doses 1.0 ml and 1.5 ml of Matrix via mesh nebulizer” NCT07372989 ↗ |